A New EBV Related Technologies of T Cells in Treating Malignant Tumors and Clinical Application

The Second Hospital of Nanjing Medical University20 enrolled

Overview

The purpose of this study is to evaluate the safety of the designed LMP1-CAR -T cells and determine whether the CAR-T cells are effective in the treatment of EBV associated malignant tumors.

Half of the patients will treat with LMP1-CAR-T cells,while the other half will receive a placebo.During the time of the treatment ,we will supervise the side effect of treated group.At last we compare the survival rate and health condition of the two groups.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Nasopharyngeal Neoplasms

Interventions

CAR-T cellsOTHER

the patients treat with CAR-T cells

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Clinical diagnosis of nasopharyngeal carcinoma Exclusion Criteria: * •pregnant woman * severe autoimmune diseases * serious infection

Locations (1)

SecondNanjingMU

Nanjing, Jiangsu, China

RECRUITING

Outcomes

Primary Outcomes

all cause mortality

Time frame: one year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.